Mixed Cellularity Hodgkin Lymphoma: A Guide for Patients With Stage 1 Disease

Mixed cellularity Hodgkin lymphoma is a subtype of Hodgkin lymphoma, a cancer that begins in the lymphatic system. The lymphatic system is part of the body’s immune system and includes lymph nodes, the spleen, bone marrow and lymph vessels. In this disease, abnormal immune cells called Reed-Sternberg cells develop and grow within lymph nodes, along with a mixture of other immune cells, which gives the subtype its name.

Stage 1 mixed cellularity Hodgkin lymphoma means the cancer is found in only one lymph node region or a single lymphatic organ. Because the disease is limited to one area, it is considered early stage and is often highly treatable.

Many patients with stage 1 Hodgkin lymphoma respond well to therapy, and long-term remission is common. Treatment decisions depend on several factors, including the location of the lymphoma, whether symptoms are present, a patient’s overall health and preferences, and how the disease responds to initial therapy. Throughout the treatment process, open communication with an oncology care team can help patients understand their options and manage side effects.

Diagnosis

Diagnosing mixed cellularity Hodgkin lymphoma typically involves several tests that confirm the type of lymphoma and determine the stage of the disease.

A biopsy is the most important step. During this procedure, a doctor removes part or all of a lymph node so that pathologists can examine the tissue under a microscope. The presence of Reed-Sternberg cells along with a mixed background of immune cells helps confirm the diagnosis of mixed cellularity Hodgkin lymphoma.

After diagnosis, imaging tests help determine how far the disease has spread. These may include CT scans or PET scans, which create detailed images of the body and can identify affected lymph nodes or organs.

Blood tests are also used to evaluate overall health and check for signs that the lymphoma may be affecting other systems. In some cases, doctors may perform a bone marrow biopsy to determine whether lymphoma cells are present in the bone marrow, although this is less common in early-stage disease.

These tests allow oncologists to determine the stage of the lymphoma and develop a treatment plan tailored to the patient.

Frontline treatment

Frontline therapy refers to the first treatment used after diagnosis. For stage 1 Hodgkin lymphoma, the goal is to eliminate the cancer while minimizing long-term side effects.

Treatment often includes combination chemotherapy. One commonly used regimen includes several drugs that work together to destroy lymphoma cells. Chemotherapy is usually given in cycles over several weeks.

Some patients may also receive radiation therapy after chemotherapy. Radiation uses high-energy beams to target and destroy lymphoma cells in the affected lymph node area. In early-stage Hodgkin lymphoma, radiation is sometimes used to reduce the risk that the disease returns.

In certain cases, doctors may tailor treatment based on how the lymphoma responds to the first cycles of chemotherapy, often evaluated through follow-up imaging scans.

Second-line treatment

Second-line treatment is used if the lymphoma does not respond to initial therapy or returns after treatment.

Options may include different chemotherapy combinations or targeted therapies designed to attack lymphoma cells more precisely. Some patients may also receive immunotherapy drugs that help the immune system recognize and destroy cancer cells.

In some cases, doctors may recommend high-dose chemotherapy followed by a stem cell transplant. This procedure replaces damaged bone marrow with healthy stem cells after intensive treatment.

Third-line and beyond

If lymphoma returns after multiple treatments, additional therapies may still be available. These may include newer targeted therapies, immunotherapy approaches or participation in clinical trials that are studying promising new treatments.

Clinical trials can provide access to therapies that are not yet widely available and may offer another option for patients whose lymphoma has been difficult to treat.

Side effects

Cancer treatments can cause side effects, although not every patient experiences them and many can be managed with supportive care.

Chemotherapy commonly causes fatigue, nausea, hair loss and a temporary drop in blood cell counts, which may increase the risk of infection. Some patients may also experience mouth sores or changes in appetite.

Radiation therapy can cause fatigue and skin irritation in the treated area. Depending on where radiation is directed, other effects may occur, such as difficulty swallowing if lymph nodes near the neck are treated.

Targeted therapies and immunotherapy may cause different side effects, including immune-related reactions or inflammation in certain organs. Oncology teams closely monitor patients during treatment to identify and manage these effects early.

Patients should discuss any symptoms with their care team, as medications, supportive treatments and lifestyle adjustments can help reduce many side effects.

Conclusion

Stage 1 mixed cellularity Hodgkin lymphoma is often highly treatable, and many patients achieve long-term remission after frontline therapy. Advances in chemotherapy, radiation techniques and targeted therapies continue to improve outcomes while aiming to reduce long-term side effects.

Every patient’s situation is unique, and treatment decisions should be made in partnership with an oncology care team. Asking questions about treatment goals, potential side effects and follow-up care can help patients better understand their options and play an active role in their care throughout the cancer journey.

Editor's note: This article is for informational purposes only and is not a substitute for professional medical advice, as your own experience will be unique. Use this article to guide discussions with your oncologist. Content was generated with AI, reviewed by a human editor, but not independently verified by a medical professional.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.